Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.73 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.73 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.73 |
| ▸ | POLG | P54098 | 2/20 | 0.69 |
| ▸ | DUT | P33316 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxycytidine Triphosphate SCHEMBL27673667 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL12729518 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL29725285 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL28008985 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL42135 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL29030090 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL1615548 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL18785037 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL703664 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL28420890 | 0.99 | POLB (0.76) | POLBP2RY2P2RY4P2RY6POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | EAGLE BIOLOGICS, INC. | 2015-03-12 | — | — | US | disclosed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150071921-A1 | LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES | IGFBP1, IGFBP5, IGF2BP1 | POLB 3895/4885P2RY2 2768/4885P2RY4 2341/4885 |
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | POLB 3337/4885P2RY2 1037/4885P2RY4 518/4885 |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | PNP, NUDT1, DUT | POLB 209/4885P2RY2 580/4885P2RY4 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.